Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | MME | P08473 | 2/20 | 0.55 |
| ▸ | BACE1 | P56817 | 4/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27983689 | 0.92 | LTA4H (0.64) | OPRM1OPRD1LTA4HMMEOPRK1 | |
| SCHEMBL30903467 | 0.90 | LTA4H (0.65) | OPRM1OPRD1LTA4HMME | |
| SCHEMBL30122976 | 0.89 | OPRM1 (0.56) | OPRM1OPRD1BACE1OPRK1BACE2 | |
| SCHEMBL30799804 | 0.88 | OPRM1 (0.60) | OPRM1OPRD1LTA4HMMEBACE1 | |
| SCHEMBL31215110 | 0.88 | OPRM1 (0.56) | OPRM1OPRD1MMEBACE1OPRK1 | |
| SCHEMBL29775590 | 0.88 | BACE1 (0.55) | OPRM1OPRD1LTA4HMMEBACE1 | |
| SCHEMBL29947099 | 0.88 | LTA4H (0.55) | OPRM1OPRD1LTA4HMMEBACE1 | |
| SCHEMBL8975237 | 0.88 | LTA4H (0.60) | LTA4HMME | |
| SCHEMBL30903454 | 0.87 | OPRK1 (0.55) | OPRM1OPRD1LTA4HMMEBACE1 | |
| SCHEMBL30799912 | 0.87 | BACE1 (0.64) | OPRM1OPRD1BACE1OPRK1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243509-A1 | METHODS FOR TREATING EYE DISEASE | MUSC FOUND FOR RES DEV (US) | 2025-07-31 | — | — | US | disclosed |
| US-11945848-B2 | Chimeric inhibitor molecules of complement activation | OMEROS CORPORATION (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230295252-A1 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION | OMEROS CORPORATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230103708-A1 | METHODS FOR TREATING EYE DISEASE | MUSC FOUND FOR RES DEV (US) | 2023-04-06 | — | — | US | disclosed |
| US-11453709-B2 | Chimeric inhibitor molecules of complement activation | OMEROS CORPORATION (US) | 2022-09-27 | — | — | US | disclosed |